Leerink Partners upgraded Bristol-Myers Squibb (NYSE:BMY) to Outperform from Market Perform on Tuesday, boosting sales ...

Leerink Partnrs increased their FY2024 earnings per share estimates for Werewolf Therapeutics in a report released on Monday, ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

In a report released yesterday, Daina Graybosch from Leerink Partners maintained a Hold rating on Turnstone Biologics Corp. (TSBX – ...

Investment analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Xencor in a ...

Beam Therapeutics (BEAM) stock gains as Leerink upgrades the biotech despite a fatality in a gene editing study, citing an ...

Dentsply Sirona (XRAY) stock fell as the company with its Q3 2024 lowered full-year outlook, prompting a downgrade from Leerink Partners. Read more here.

Fintel reports that on November 7, 2024, Leerink Partners upgraded their outlook for Zymeworks (NasdaqGS:ZYME) from Market Perform to Outperform. As of October 22, 2024, the average one-year price ...

Leerink Partners has recently resumed MannKind Corp (MNKD) stock to Outperform rating, as announced on September 9, 2024, according to Finviz. Earlier, on June 13, 2024, Rodman & Renshaw had initiated ...

Fintel reports that on November 7, 2024, Leerink Partners downgraded their outlook for DENTSPLY SIRONA (WBAG:XRAY) from Outperform to Market Perform. There are 910 funds or institutions reporting ...